Chemotherapy

What is Chemotherapy?

Chemotherapy is a group of toxic drugs that kill cells (mesothelioma, other cancers, and healthy cells) by damaging their DNA. Chemotherapy is a cytotoxic therapy, meaning it kills cells. Chemo drugs target rapidly growing cancer cells, but they can also affect healthy cells that grow rapidly such as blood cells. The effect of these drugs on both cancer and normal cells often causes chemo side effects.

Alimta (Pemetrexed) and Cisplatin

As of this writing, the only FDA approved chemotherapy for mesothelioma is a combination of Alimta (pemetrexed) and cisplatin. In February 2004, the Food and Drug Administration approved pemetrexed for the treatment of malignant pleural mesothelioma in combination with cisplatin for patients whose disease is either inoperable or who are not otherwise candidates for curative surgery. Patients who take this chemo regimen are often prescribed folic acid and vitamin B12 supplement to help reduce side effects from the chemotherpay. Patients are usually prescribed corticosteroids to reduce the risk of skin rashes as well.

The recommended dose of pemetrexed is 500 mg/m administered as an intravenous infusion over 10 minutes on day 1 of each 21-day cycle together with cisplatin at a dose of 75 mg/m infused over 2 hours beginning 30 minutes after the pemetrexed infusion.

The Clinical Trial that Approved Alimta (Pemetrexed) and Cisplatin

There was one key clinical trial that led to the FDA approval of this regimen for mesothelioma. Two hundred twenty-six pleural mesothelioma patients were randomized to receive pemetrexed and cisplatin, while 222 patients were randomized to receive cisplatin alone. The primary study end point was survival. Median survival times were 12.1 months for the pemetrexed plus cisplatin treatment group and 9.3 months for the cisplatin alone group.

Median time to progression (regrowth of tumor) was longer in the pemetrexed/cisplatin arm of the study, 5.7 months versus 3.9 months. This means that the mesothelioma patients who received both drugs had their tumors return a median of 1.8 months longer versus those who only got one drug.

Like most chemo drugs, pemetrexed kills blood cells so the most common adverse events were neutropenia, fatigue, leukopenia, nausea, dyspnea, and vomiting.

On February 4, 2004, pemetrexed was approved by the FDA in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is inoperable or who are otherwise not candidates for curative surgery.

Related Posts

Standard Mesothelioma Chemotherapy with Avastin: More Good News - Another new study suggests that adding a third drug to standard mesothelioma chemotherapy might lead to better treatment outcomes.  Several recent studies show immunotherapy drugs like Keytruda and IMFINZI may boost the effectiveness of chemotherapy.  The newest report focuses on the monoclonal antibody, bevacizumab (Avastin). Japanese researchers back up what others have found. They say most patients did well on a combination of Avastin and standard mesothelioma chemotherapy.  Drug Blocks Blood Vessel Formation Like all body tissues, mesothelioma tumors need blood vessels to grow and thrive. Angiogenesis is the process by which tumors create their own new blood vessels.  Avastin works by blocking this process. Without an adequate blood supply, a mesothelioma tumor may be more susceptible to standard mesothelioma … Continue reading Standard Mesothelioma Chemotherapy with Avastin: More Good News »

Electrochemotherapy for Mesothelioma May Relieve Pain, Shrink Tumors - There’s new evidence that a technique called electrochemotherapy (ECT) may relieve mesothelioma pain and even shrink tumors. It may be an option for patients who have not had success with other treatments.  Cancer researchers with the Italian Ministry of Health recently conducted the first test of electrochemotherapy on pleural mesothelioma and several other rare cancers.  They found that zapping tumors with electricity helped the medicine go through the cell membranes. The treatment reduced pain for every patient tested. In most cases, it also slowed down or even temporarily stopped their tumor growth.   How Electrochemotherapy Works Malignant mesothelioma is a rare membrane cancer. Chemotherapy is the main treatment for mesothelioma. But more than half of mesothelioma tumors do not respond to … Continue reading Electrochemotherapy for Mesothelioma May Relieve Pain, Shrink Tumors »

Triple Therapy May Become New First-Line Treatment for Mesothelioma - A combination of three powerful mesothelioma therapies could become a new first-line treatment for mesothelioma if an upcoming clinical trial is successful. The makers of the experimental immunotherapy drug ONCOS-102 announced the new clinical trial. It will enroll up to 100 mesothelioma patients from around the world.  The trial will test ONCOS-102 along with Keytruda (pembrolizumab) and standard chemotherapy. Keytruda is an immune checkpoint inhibitor. Both ONCOS-102 and Keytruda have shown some promise when combined with mesothelioma chemotherapy. Targovax hopes that the triple therapy approach will produce an even more powerful first-line treatment for mesothelioma. Clinic Trial of ONCOS-102 A first-line treatment is a treatment for mesothelioma patients who have not yet had any other therapies. Most patients start with … Continue reading Triple Therapy May Become New First-Line Treatment for Mesothelioma »

Long Term Peritoneal Mesothelioma Survival with NIPEC - A new report suggests that long term peritoneal mesothelioma survival may be possible with a treatment called NIPEC and the drug paclitaxel.  NIPEC stands for normothermic intraperitoneal chemotherapy. It is similar to the heated chemotherapy that many peritoneal mesothelioma patients now get. But NIPEC is delivered through a catheter over time and at room temperature.  The new article details the long term peritoneal mesothelioma survival of six patients on NIPEC with paclitaxel. It comes from one the nation’s leading experts in this form of mesothelioma, Paul Sugarbaker, MD.  Even though the sample size is small, Dr. Sugarbaker says the results are impressive enough to warrant further study.  HIPEC and Mesothelioma Treatment Peritoneal mesothelioma accounts for about 20 percent of mesothelioma … Continue reading Long Term Peritoneal Mesothelioma Survival with NIPEC »

Second-Line Mesothelioma Treatment with Ramucirumab - A combination of ramucirumab (CYRAMZA) and gemcitabine creates a promising second-line mesothelioma treatment. New research shows the combination nearly doubled survival in a group of patients whose tumors kept growing with standard therapy.  Italian researchers shared their findings at the virtual annual meeting of ASCO. ASCO is one of the largest gatherings of cancer doctors in the US. First-Line Mesothelioma Treatment Failure For most mesothelioma patients, chemotherapy with Alimta is the first-line treatment. This does keep the cancer in check for some patients. But after a while, mesothelioma tumors almost always come back. Chemotherapy only extends survival by about four months.  Doctors have tested many different approaches to second-line mesothelioma treatment.  Some of the therapies tested are: Additional rounds of … Continue reading Second-Line Mesothelioma Treatment with Ramucirumab »

Immunotherapy with Durvalumab: Record Survival in Inoperable Mesothelioma - There is new evidence that the immunotherapy drug durvalumab may make chemotherapy more effective for people with inoperable pleural mesothelioma. Researchers recently achieved record mesothelioma survival times with this combination. Mesothelioma is a rare cancer with a poor prognosis. Surgery can sometimes help if it is caught early. But only a small percentage of patients are candidates for mesothelioma surgery. Most have chemotherapy, which is only moderately effective.  But new research presented to the nation’s largest gathering of cancer doctors shows the immunotherapy drug durvalumab may help.  Doctors at Johns Hopkins combined durvalumab with standard mesothelioma chemotherapy. Study participants lived an average of 8 months longer than is typical with this disease.  If further studies confirm the benefit, it could … Continue reading Immunotherapy with Durvalumab: Record Survival in Inoperable Mesothelioma »

Chemoperfusion Treatment for Mesothelioma: Chemo Without the Side Effects? - New research suggests that chemoperfusion treatment for mesothelioma may buy patients more time without the side effects of traditional chemotherapy.  Chemoperfusion treatment involves injecting cancer-killing drugs directly into the vessels that feed a pleural mesothelioma tumor.  The research was presented during a virtual session of the Society of Interventional Radiology’s annual meeting. Researchers showed how this novel approach could improve quality of life for mesothelioma patients.  Limitations of Chemotherapy Pleural mesothelioma is a rare cancer with few treatment options. Most mesothelioma patients start with chemotherapy. Alimta (pemetrexed) is the primary chemotherapy drug for mesothelioma.  But chemotherapy has drawbacks that chemoperfusion treatment for mesothelioma might avoid.  Conventional chemotherapy circulates drugs throughout the body. That means that normal cells can absorb them … Continue reading Chemoperfusion Treatment for Mesothelioma: Chemo Without the Side Effects? »

Predicting Kidney Damage from Chemotherapy for Mesothelioma - It may be possible to predict which mesothelioma patients are at risk for kidney damage from chemotherapy and take steps to prevent it.  Japanese cancer researchers have linked a protein called megalin to cisplatin-related nephrotoxicity.  Cisplatin is one of the main drugs used to treat mesothelioma. The researchers say people with more megalin in their urine are more likely to have kidney damage from chemotherapy with cisplatin.  Kidney Damage is a Risk of Chemotherapy Malignant mesothelioma is a rare cancer with no cure. Although scientists are working on other options, chemotherapy is the main treatment for mesothelioma. Most patients have a combination of Alimta (pemetrexed) and the platinum-based drug cisplatin. One of the biggest risks with cisplatin is kidney damage … Continue reading Predicting Kidney Damage from Chemotherapy for Mesothelioma »

Second Line Mesothelioma Treatment Shot Down in New Study - Italian researchers say there is good news and bad news about a proposed second line mesothelioma treatment.  The good news is that the treatment did not cause major side effects in the patients who tried it. The bad news is that it also did not help them live any longer.  The treatment is a mixture of gemcitabine and imatinib. Animal studies suggested that the combination might improve mesothelioma survival.  The newly-published study shows the second line mesothelioma treatment did help control the disease in most patients. But the 23 patients who tried it only lived for a median of 5.7 months. That was not enough for doctors to recommend the combination. Mesothelioma Chemotherapy and Survival The most common first line … Continue reading Second Line Mesothelioma Treatment Shot Down in New Study »

Injectable Pemetrexed for Mesothelioma Now Available for the First Time - The FDA has cleared injectable pemetrexed for mesothelioma after two drug companies settled a patent dispute over the medication in December. Until now, the chemotherapy drug pemetrexed has only been available for infusion. In this form, it is called Alimta and is distributed by Eli Lilly.  But New Jersey-based Eagle Pharmaceuticals wanted to develop a form of injectable pemetrexed for mesothelioma. They received tentative approval for the drug in 2018, but it was not until the patent issue was settled that the final approval was granted.  The drug may shorten the duration of treatment for some patients with malignant mesothelioma.  Pemetrexed the Primary Mesothelioma Treatment Malignant mesothelioma is an intractable cancer that grows on the membranes around internal organs. Patients … Continue reading Injectable Pemetrexed for Mesothelioma Now Available for the First Time »